patent.fyi
Applications  /  US 2026/0354380
United States Patent Application Publication

US 2026/0354380 A1

Published
Nov 12, 2026
Filed
Jul 31, 2023
Earliest date on the face
Aug 2, 2022
Classification
A01N 43/78
First published here
Nov 18, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Oxadiazole linker joins fragments

What ifWhat if a 1,2,4-oxadiazole ring joined the two fragments at Q?
Claim language“Q is —C(═O)—N(R5)—, or —N(R5)—C(═O)—”

The fragments attach to carbon atoms 3 and 5 of the oxadiazole. The aromatic ring fixes the two attachment directions and provides hydrogen-bond acceptor sites.

1.3Hydroxyl group tunes polarity

What ifWhat if the phenyl group at R5 carried a para hydroxyl substituent?
Claim language“substituted with halogen or CN”

The phenyl ring attaches to the amide nitrogen through carbon 1 and carries OH at carbon 4. The hydroxyl group adds a hydrogen-bond donor and acceptor site at the outer edge of the ring.

1.4Methoxy group occupies R1

What ifWhat if a methoxy group attached through oxygen at R1?
Claim language“or NR6R7”

An oxygen atom connects the scaffold to a terminal methyl group. The oxygen provides a hydrogen-bond acceptor and positions the methyl group one bond beyond the scaffold attachment site.

1.6Ethynyl group occupies R2

What ifWhat if a terminal ethynyl group occupied R2?
Claim language“or halogen”

The scaffold bonds directly to one carbon of a carbon–carbon triple bond, and the second carbon bears hydrogen. The triple bond holds the two carbons in a linear arrangement that projects from the attachment site.

1.11Ring nitrogen occupies B4

What ifWhat if a pyridine-type nitrogen occupied B4?
Claim language“is CRB4”

The nitrogen bonds to the two neighboring ring atoms and contributes one electron to the aromatic π system. Its lone pair lies in the plane of the ring and provides a hydrogen-bond acceptor at B4.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Bait stations in ornamental plant nurseries

A covered bait station houses a removable cellulose pad containing a formula I compound dispersed in a starch gel. The station sits at bench legs or floor junctions where monitoring indicates crawling arthropod activity. Side openings admit target arthropods, and the cover shields the pad from overhead irrigation.

Component substitution

Ester linkage in the pyrazolo scaffold

An ester group, —C(═O)—O—, replaces the —C(═O)—N(R5)— linker while preserving the attachment positions on the flanking fragments. The carbonyl-bearing fragment provides the carboxylic acid component, and the opposite fragment provides the hydroxyl component for ester formation. Liquid chromatography measures hydrolysis during storage, and a separate contact assay measures activity against the target arthropod.

Oxadiazole linkage in the pyrazolo scaffold

A 2,5-disubstituted 1,3,4-oxadiazole ring replaces the amide linker, with the two flanking fragments attached at the ring's carbon atoms. The corresponding diacylhydrazine carries one flanking fragment on each acyl group and undergoes cyclodehydration to form the ring. A concentration series in a leaf-disc assay measures arthropod mortality for the resulting compound.

Parameter or scale variation

Coating loads for seed treatment trials

A rotary seed coater applies an aqueous suspension of a formula I compound to three independent 1 kg seed batches at 0.1, 0.3, and 1.0 g of active ingredient per kilogram of seed. Each batch receives the same total liquid volume by adjusting the concentration of the active ingredient in the suspension. The coated batches dry separately, and seed subsamples are tested for loading uniformity and germination before pest exposure.

Combination with existing systems

Directed spray on a transplanting machine

A transplanting machine carries a separate agitated tank containing an aqueous suspension of a formula I compound. A metering pump feeds a shielded nozzle mounted between the transplant placement mechanism and the closing wheels. A sensor at the placement mechanism triggers a single spray pulse onto the root plug and adjacent soil before the wheels close the planting slot.

Automated or data-driven variant

Camera guided greenhouse spot treatment

Fixed cameras image sticky monitoring cards, and software counts target arthropods and associates each card with a greenhouse bench zone. The controller compares counts from successive images against a configured threshold for each zone. When the threshold is reached, the controller opens the valve for that zone and meters a spray suspension containing a formula I compound through its dedicated nozzle bank.

Specific version of a part

Cyclopropyl on the amide nitrogen

R5 is cyclopropyl, with one ring carbon bonded directly to the amide nitrogen. The attached carbon bears one hydrogen, and the other two ring carbons are methylene groups.

Trifluoromethyl group at R1

R1 is a one-carbon alkyl group with three fluorine substituents. The carbon bonds directly to the scaffold, and the three carbon–fluorine bonds make the group electron withdrawing.

Cyanomethyl group at R2

R2 is a methyl group bearing a cyano substituent. The methylene carbon connects the scaffold to the nitrile carbon, and the terminal nitrile nitrogen acts as a hydrogen-bond acceptor.

Aromatic nitrogen at B1

B1 is a pyridine-type ring nitrogen bonded to its two neighboring ring atoms. The nitrogen contributes one electron to the aromatic π system, and its in-plane lone pair acts as a hydrogen-bond acceptor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0099236 A1
Published
Apr 16, 2009
Filed
Oct 8, 2008
Class
A61K 31/4439
Document BUS 2019/0307776 A1
Published
Oct 10, 2019
Filed
Jun 28, 2017
Class
A61K 31/58
Claim 1
Document A
Document B
1.1Q is —C(═O)—N(R5)—, or —N(R5)—C(═O)—
1.2R5 is H, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-alkyl-C1-C6-alkoxy or C1-C6-alkyl-C3-C6-cycloalkyl, phenyl, 5- or 6-membered heteroaryl, —CH2-phenyl, —CH2-5- or 6-membered heteroaryl, 1,3-dioxolan-2-ylmethyl, or halogen
Ra is C1-6 alkyl, NR2R2, Rb is —H, —C1-6 alkyl, —COR3, —SO2R3, —SONR3R3, R5 is selected from —H, —C1-6 alkyl, —C3-6 cycloalkyl, —C1-6 alkylsubstituted alkyl, —C1-6 alkyl-NR8R9, —COR6, —COCOR6, —SO2R7 and —SO2NR2R2; with the proviso that only one of R4 or R5 can be selected from —COR6, —COCOR6, —SO2R7 and —SO2NR2R2;
B · US 2019/0307776 A1 · claim 28
1.3wherein the alkyl, cycloalkyl, phenyl, and heteroaryl moieties are unsubstituted or substituted with halogen or CN
The phenyl group of the benzyl moiety could be optionally substituted by 1-3 moieties independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy and cyano. “Cx-C7” notation indicates a structural element comprised of carbons numbering between ‘x’ and ‘y’.
B · US 2019/0307776 A1 · ¶ 73
1.4R1 is H, C1-C6-alkyl, C3-C6-cycloalkyl, halogen, or NR6R7
1.5wherein the alkyl and cycloalkyl moieties are unsubstituted or substituted with halogen or CN
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated.
A · US 2009/0099236 A1 · ¶ 83
1.6R2 is H, C1-C6-alkyl, C3-C6-cycloalkyl, or halogen
Ra is: hydrogen; fluoro; or alkyl;
A · US 2009/0099236 A1 · claim 28
1.7wherein the alkyl and cycloalkyl moieties are unsubstituted or substituted with halogen or CN
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated.
A · US 2009/0099236 A1 · ¶ 83
1.8B1 is N or CRB1
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of the
A · US 2009/0099236 A1 · ¶ 81
1.9B2 is N or CRB2
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of the
A · US 2009/0099236 A1 · ¶ 81
1.10B3 is N or CRB3
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of the
A · US 2009/0099236 A1 · ¶ 81
1.11B4 is CRB4
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of the
A · US 2009/0099236 A1 · ¶ 81
1.12RB1, RB2, RB3, and RB4 independently of each other are H, halogen, CN, C1-C6-alkyl, C3-C6-cycloalkyl, or C1-C6-alkoxy wherein the alkyl, alkoxy, and cycloalkyl moieties are unsubstituted or substituted with halogen D is the moiety DA or DB, R3 is H, C1-C6-alkyl or C3-C6-cycloalkyl wherein the alkyl and cycloalkyl moieties are unsubstituted or substituted with halogen or CN R4 is H, C1-C6-alkyl, or C3-C6-cycloalkyl wherein the alkyl and cycloalkyl moieties are unsubstituted or substituted with halogen, —O—(C═O)—C1-C6-alkyl, —O—(CO)—C1-C6-alkoxy, or CN B is a 5- or 6-membered carbocyclic group wherein 1 or 2 CH2 moieties of the carbocyclic group may be optionally are replaced by a carbonyl group, O, or S wherein the carbocyclic group is unsubstituted or substituted with Rh Ar1 is phenyl or 5- or 6-membered heteroaryl, which are unsubstituted or substituted with RAr1 wherein RAr1 is halogen, SF5, NO2, OH, CN, C1-C6-alkyl, C1-C6-alkoxy, C3-C6-cycloalkyl, C3-C6-heterocyclyl, C3-C6-cycloalkoxy, C2-C6-alkenyl, C2-C6-alkynyl wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, C3-C6-heterocyclyl, and cycloalkoxy moieties are unsubstituted or substituted with Rf C(═O)—ORa, NRbRc, C1-C6-alkylene-CN, C(═O)—NRbRc, C(═O)Rd, NHS(═O)mRe, S(═O)mRe, —N═S(═O)—(C1-C6-alkyl)2, SO2NRbRc, or S(═O)mRe R6 and R7 are, identical or different, H, C1-C6-alkyl, C3-C6-cycloalkyl, phenyl, —CH2-phenyl, 5- or 6-membered heteroaryl, —CH2-5- or 6-membered heteroaryl, 1,3-dioxolan-2-ylmethyl, or 2-(methylamino)-2-oxo-ethyl wherein the alkyl, cycloalkyl, phenyl, and heteroaryl moieties are unsubstituted or substituted with halogen, CN, C1-C6-alkyl or C1-C6-alkoxy Ar2 is phenyl or 5- or 6-membered heteroaryl, which are unsubstituted or substituted with RAr2 wherein RAr2 is halogen, CN, —SCN, —SF5, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy-C1-C4-alkyl, C1-C6-alkoxy-C1-C4-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkoxy, C3-C6-cycloalkyl-C1-C4-alkyl, C3-C6-cycloalkoxy-C1-C4-alkyl wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, and cycloalkoxy moieties are unsubstituted or substituted with halogen, C(═O)—ORa, NRbRc, C1-C6-alkylene-CN, C(═O)NRbRc Ra, Rb, and Rc are, identical or different, H, C1-C6-alkyl, C2-C6-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, —C(═O)—C1-C6-alkyl wherein the alkyl, alkenyl, and cycloalkyl moieties are unsubstituted or substituted with halogen, Rd is H, C1-C6-alkyl Re is C1-C6-alkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl wherein the alkyl and cycloalkyl moieties are unsubstituted or substituted with halogen or CN Rf is halogen, OH, CN, SCN, —SF5, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy-C1-C4-alkyl, C1-C6-alkoxy-C1-C4-alkoxy, C3-C6-cycloalkyl, C3-C6-cycloalkoxy, C3-C6-cycloalkyl-C1-C4-alkyl, C3-C6-cycloalkoxy-C1-C4-alkyl wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, and cycloalkoxy moieties are unsubstituted or substituted with halogen Rh is halogen, C1-C6-alkyl, or C1-C6-alkoxy m is 0, 1, or 2: and N-oxides, stereoisomers, tautomers, and agriculturally or veterinarily acceptable salts thereof.
R1 is: (a) aryl selected from phenyl and naphthyl, each optionally substituted; or (b) heteroaryl selected from indolyl, indazolyl, pyridinyl, thienyl, furanyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuranyl, benzothiophenyl or benzoxazinyl, each optionally substituted;
A · US 2009/0099236 A1 · claim 28
Y is selected from —COOR2, —C(O)NR2SO2R3, —C(O)NHSO2NR2R2, —NR2SO2R2, —SO2NR2R2, —C3-6 cycloalkyl-COOR2, —C2-6 alkenyl-COOR2, —C2-6 alkynyl-COOR2, —C1-6 alkyl-COOR2, —NHC(O)(CH2)p—COOR2, —SO2NR2C(O)R2, -tetrazole, and —CONHOH, wherein p is 1-6; alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from —H, -halo, -hydroxyl, —C1-6 alkyl, —C1-6 alkoxy, —COOR2, —CN, —NO2, —CF3, —SO2, —NR26R27, —CONR26R27,
B · US 2019/0307776 A1 · ¶ 13

An empty cell means only that no passage was reproduced there.

Statements in these documents
In particular, compounds of the present invention are useful for treatment of diseases associated with monoamine reuptake inhibitors.
A · US 2009/0099236 A1 · ¶ 2
Dual reuptake inhibitors of serotonin and norepinephrine also offer potential treatments for disorders and disease states of the urinary tract, and for pain and inflammation.
A · US 2009/0099236 A1 · ¶ 4
Despite the armamentarium of agents and drug combinations, there remains a medical need for new anti-retroviral agents, due in part to the need for chronic dosing to combat infection.
B · US 2019/0307776 A1 · ¶ 4
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions, and their use in inhibiting HIV and treating those infected with HIV or AIDS.
B · US 2019/0307776 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0354380 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354380/, SHA-256 42c82998f82210cd10f94278af5f8848278f519813580081e6991c70b2d8cd9a
First published
Permanent addresshttps://patent.fyi/US20260354380/
Content fingerprint (SHA-256)42c82998f82210cd10f94278af5f8848278f519813580081e6991c70b2d8cd9a
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi